Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria) in Australian Defence Force personnel

On return from duty in North Solomons Province (including Bougainville Island), Papua New Guinea, 586 Australian Defence Force personnel received either primaquine (14-d) or tafenoquine (3-d) post-exposure malaria prophylaxis. Within 12 months, 6 of the 214 volunteers receiving primaquine and 7 of 378 receiving tafenoquine had developed vivax malaria. Overall, volunteers preferred the shorter course of tafenoquine.

Plasma concentrations of tafenoquine, a new long-acting antimalarial agent, in Thai soldiers receiving monthly prophylaxis

We measured plasma tafenoquine concentrations in Thai soldiers given a monthly regimen of tafenoquine to determine whether these concentrations adequately suppressed malarial infections on the Thai- Cambodian border. After receiving a treatment course of artesunate and doxycycline, 104 male soldiers were administered a loading dose of tafenoquine ( 400 mg daily for 3 days), followed by tafenoquine monthly ( 400 mg every 4 weeks) for 5 months. Consecutive monthly mean ( +/- standard deviation) trough plasma tafenoquine concentrations were 223 +/- 41, 127 +/- 29, 157 +/- 51. 120 +/- 24, and 88 +/- ng/ mL. Only 1 soldier developed malaria during the study. At the time of malaria diagnosis, his plasma tafenoquine concentration was 40 ng/ mL, which was similar to 3- fold lower than the trough concentrations of the other soldiers. Although low tafenoquine concentrations appear to be uncommon, additional investigations are needed to determine the relationship between plasma tafenoquine concentrations and suppression of malaria.

Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P-falciparum malaria

We assessed monthly doses of tafenoquine for preventing Plasmodium vivax and multidrug-resistant P. falciparum malaria. In a randomized, double-blind, placebo-controlled study, 205 Thai soldiers received either a loading dose of tafenoquine 400 mg ( base) daily for 3 days, followed by single monthly 400-mg doses (n = 104), or placebo (n = 101), for up to 5 consecutive months. In volunteers completing follow-up (96 tafenoquine and 91 placebo recipients), there were 22 P. vivax, 8 P. falciparum, and 1 mixed infection. All infections except 1 P. vivax occurred in placebo recipients, giving tafenoquine a protective efficacy of 97% for all malaria (95% confidence interval [CI], 82%-99%), 96% for P. vivax malaria (95% CI, 76%-99%), and 100% for P. falciparum malaria ( 95% CI, 60%-100%). Monthly tafenoquine was safe, well tolerated, and highly effective in preventing P. vivax and multidrug-resistant P. falciparum malaria in Thai soldiers during 6 months of prophylaxis.

Treatment of acute vivax malaria with tafenoquine

Tafenoquine is an 8-aminoquiniline related to primaquine with preclinical activity against a range of malaria species. We treated two acute cases of vivax malaria with tafenoquine (800 mg over three days) atone, instead of conventional chloroquine (1500 mg over three days) and primaquine (420 mg over 14 days). In addition to the convenience of this regimen, the rapid parasite clearances observed, coupled with a good clinical response and lack of recrudescence or relapse, indicate that further investigation of tafenoquine in the treatment of vivax malaria is warranted. (C) 2004 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.

Variabilidade de Fusarium oxysporum F. lycopersici (Wr) Sny & Hans em São Paulo

A Murcha de Fusarium em tomateiro não está sendo eficientemente controlada no Estado de São Paulo, devido a falta de variedades resistentes, adequadas ao mercado. Como na produção destas, variedades resistentes é necessário um estudo sôbre a variabilidade do fango quanto a raças fisiológicas os autores pesquisaram 48 linhagens de Fusarium coletados em todo o Estado de São Paulo e através de testes em variedades diferenciais Bonny Best., Santa Cruz (Kobayashi) e S-34 em condições de casa de vegetação com contrôle parcial de temperatura e inoculaçôes artificiais. Concluiram que das 48 linhagens estudadas uma desta apresentava reação de raça 2 as demais 47 a da raça 1 sendo possível reparar as linhagens pelo gráu de patogenicidade.

Öfwer wår swenska hassel

Sis. myös: [Grat., lat. runo] / D. E. Högman . [Grat., ruots. pr.] / Johan Wegelius . [Grat., ruots. pr.] / J. P. Bergh

Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study

Clinical trials indicate that amifostine may confer protection on various normal tissues without attenuating anti-tumor response. When administered prior to chemotherapy or radiotherapy, it may provide a broad spectrum of cytoprotection including against alkylating drugs. The mechanism of protection resides in the metabolism at normal tissue site by membrane-bound alkaline phosphatase. Toxicity of this drug is moderate with hypotension, nausea and vomiting, and hypocalcemia being observed. We report a phase II study using amifostine as a protective drug against high-dose cyclophosphamide (HDCY) (7 g/m2), used to mobilize peripheral blood progenitor cells (PBPC) and to reduce tumor burden. We enrolled 29 patients, 22 (75.9%) affected by aggressive and 7 (24.1%) by indolent non-Hodgkin's lymphoma (NHL), who were submitted to 58 infusions of amifostine and compared them with a historical group (33 patients) affected by aggressive NHL and treated with VACOP-B followed by HDCY. The most important results in favor of amifostine were the reduction of intensity of cardiac, pulmonary and hepatic toxicity, and a significant reduction of frequency and severity of mucositis (P = 0.04). None of the 29 patients died in the protected group, while in the historical group 2/33 patients died because of cardiac or pulmonary toxicity and 2 patients stopped therapy due to toxicity. Amifostine did not prevent the aplastic phase following HDCY. PBPC collection and hematological recovery were adequate in both groups. The number of CFU-GM (colony-forming units-granulocyte/macrophage) colonies and mononuclear cells in the apheresis products was significantly higher in the amifostine group (P = 0.02 and 0.01, respectively). Side effects were mild and easily controlled. We conclude that amifostine protection should be useful in HDCY to protect normal tissues, with acceptable side effects.

Same nolmay catechesis, thet är, wår christeligha hufwud stycken, eller troos articklar medh s.d. Luth. förklarning vppå lappespråk förwendt och aff then edle och wälborne herre, her Johan Skytte, frijherre til Duderoff, herre til Grönsöö, strömsrŭ och Elffwesiö, riddare, Sweriges rijkes rådh och general gubernator i Liffland och Ingermanneland, laghman öffuer Norre Finland, sampt Vbsala Academiae cantzler, etc. Bestelt til at tryckias medh eghen omkostnadt. Procurante, O. P. N

Arkit: A-B8 C4.

Same nolmay catechesis, thet är, wår christeligha hufwud stycken, eller troos articklar medh s.d. Luth. förklarning vppå lappespråk förwendt och aff then edle och wälborne herre, her Johan Skytte, frijherre til Duderoff, herre til Grönsöö, strömsrŭ och Elffwesiö, riddare, Sweriges rijkes rådh och general gubernator i Liffland och Ingermanneland, laghman öffuer Norre Finland, sampt Vbsala Academiae cantzler, etc. Bestelt til at tryckias medh eghen omkostnadt. Procurante, O. P. N

Arkit: A-B8 C4.

Same nolmay catechesis, thet är, wår christeligha hufwud stycken, eller troos articklar medh s.d. Luth. förklarning vppå lappespråk förwendt och aff then edle och wälborne herre, her Johan Skytte, frijherre til Duderoff, herre til Grönsöö, strömsrŭ och Elffwesiö, riddare, Sweriges rijkes rådh och general gubernator i Liffland och Ingermanneland, laghman öffuer Norre Finland, sampt Vbsala Academiae cantzler, etc. Bestelt til at tryckias medh eghen omkostnadt. Procurante, O. P. N

Arkit: A-B8 C4.

WR-1

Dark brown sediment with clasts ranging from small to large. The sample is mostly made up of large clasts. Clast shape ranges from angular to sub-angular. Necking structures are common throughout this sample and can mainly be seen between larger aggregates. Edge-to-edge grain crushing, crushed grains, and some lineations can also be seen.

WR-2

Dark brown sediment with clasts ranging from small to large in size. Clast shape ranges from angular to sub-rounded. The main domain mainly contains larger aggregates. There is one domain inclusion in this sample. It mainly contains small and medium sized clasts, and contains many lineations. Necking structures can be commonly seen in the main domain between larger aggregates. This sample also contains many elongated clasts and inclusions of clay material.